AbbVie raised its 2025 profit guidance on Friday after posting better-than-expected third-quarter results, powered by continued momentum in its newer immunology drugs Skyrizi and Rinvoq. The therapies have become critical growth engines as the company navigates the post-Humira era, following the blockbuster’s U.S. biosimilar competition that began last year.
Despite the earnings beat, AbbVie shares slipped nearly 4% in early trading as its aesthetics division — which includes Botox — reported a 3.7% decline from a year earlier. Analysts noted persistent softness in consumer demand for cosmetic treatments amid economic uncertainty and inflation pressure.
“Another weaker quarter for the Aesthetics business could raise some eyebrows,” BMO Capital Markets analyst Evan Seigerman wrote, pointing to ongoing headwinds across key brands including Botox and facial fillers. AbbVie executives acknowledged slower-than-expected global aesthetics spending, with chief commercial officer Jeffrey Stewart saying economic stress continues to weigh on discretionary demand.
The company now expects adjusted annual earnings per share between $10.61 and $10.65, up from its prior range of $10.38 to $10.58, reflecting confidence in underlying growth drivers beyond the aesthetics portfolio.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
